Sector
PharmaceuticalsOpen
₹8.55Prev. Close
₹9Turnover(Lac.)
₹0.08Day's High
₹8.55Day's Low
₹8.5552 Week's High
₹052 Week's Low
₹0Book Value
₹-94.79Face Value
₹10Mkt Cap (₹ Cr.)
3.42P/E
0EPS
0Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -25.23 | 8.38 | 6.78 | 2.31 |
Net Worth | -21.23 | 12.38 | 10.78 | 6.31 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Revenue | 70.69 | 186.54 | 152.85 | 113.67 |
yoy growth (%) | -62.1 | 22.03 | 34.46 | |
Raw materials | -55.48 | -131.27 | -86.68 | -57.77 |
As % of sales | 78.48 | 70.37 | 56.7 | 50.82 |
Employee costs | -11.7 | -23.03 | -18.25 | -16.73 |
| Y/e 31 Mar( In .Cr) | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Profit before tax | -13.33 | 1.6 | 4.37 | 2.32 |
Depreciation | -0.92 | -1.13 | -0.89 | -0.87 |
Tax paid | -1.3 | 0 | 0.09 | -0.71 |
Working capital | -29.4 | -10.46 | 30.22 | |
Other operating items |
| Y/e 31 Mar | Jun-2014 | Jun-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -62.1 | 22.03 | 34.46 | |
Op profit growth | -130.93 | 0.32 | 85.06 | |
EBIT growth | -137.98 | -3.06 | 79.71 | |
Net profit growth | -2,203.24 | -64.27 | 178.63 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Anuj Saxena
Director
Alok Saxena
Company Secretary
Prem Iyer
Director
Ravani Mohammed Abdul Khader
Director
Kader Mohammed Davawala
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Elder Health Care Ltd
Summary
Incorporated on 21 Mar.88, Elder Health Care (EHCL) was promoted by Jagdish Saxena and Elder Pharmaceuticals (EPL). The promoter also has interests in EPl, Semit Pharmaceuticals and Elder Projects.The company came out with a Rs 1.05-cr public issue in Feb.94 (in accordance with the OTCEI guidelines) to finance the acquisition of plant and machinery for its unit at Patalganga near Mumbai, to set up R&D facilities and to supplement working capital.The companys products include topical corticosteroids, cloxacillin and its combinations, quinolones, amoebicides, opthalmological combinations, vitamin / mineral / calcium supplements, topical antibiotics and dressings. The company has obtained licences from international pharmaceutical organisations like Oxo Chemie, Germany, and Advance Biofactures Corporation, US.The company has been appointed as the licensed manufacturer of the internationally renowned Tiger Balm of Singapore and production has started at its Patalganga unit.
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
